;12(1-2):28.SAŽETAK: Povišeni arterijski tlak (AT) vodeći je globalni čimbenik rizika za kardiovaskularne bolesti i kronične bubrežne bolesti. Stoga su uz promjene u životnome stilu očito potrebni i djelotvorni antihipertenzivni lijekovi kako bi se bolesnicima pružilo ne samo ublaživanje simptoma nego i kardiovaskularna zaštita. Kliničko ispitivanje VICTORY provedeno je kako bi se procijenila djelotvornost i sigurnost monoterapije valsartanom (Valsacor ® ) i liječenja kombinacijom fiksnih doza (KFD) valsartana i hidroklorotiazida (Valsacombi ® ) u širokoj populaciji bolesnika s blagom do umjerenom arterijskom hipertenzijom. Ukupno je 365 bolesnika bilo uključeno u šesnaestotjedno međunarodno, multicentrično, otvoreno, prospektivno ispitivanje. Bolesnici su počeli liječenje s 80 mg valsartana na dan, što se zatim moglo titrirati do 320 mg dnevno ili kombinirati s hidroklorotiazidom u KFD kako bi se postigla ciljna vrijednost AT-a. Rezultati kliničkog ispitivanja VICTORY pokazali su da valsartan i KFD valsartana i hidroklorotiazida djelotvorno smanjuju AT u bolesnika s blagom do umjerenom arterijskom hipertenzijom te imaju vrlo dobar profil podnošljivosti.SUMMARY: Raised blood pressure (BP) is the leading global risk factor for cardiovascular disease and chronic kidney disease. Thus, in addition to lifestyle changes effective antihypertensive medication is clearly needed to provide not only symptomatic relief but also cardiovascular protection. The VIC-TORY trial was performed to assess the efficacy and safety of valsartan monotherapy (Valsacor ® ) and therapy with the fixed-dose combination (FDC) of valsartan and hydrochlorothiazide (Valsacombi ® ) in a broad population of patients with mild to moderate arterial hypertension. A total of 365 patients were enrolled in this 16-week, international, multicentre, open-label, prospective trial. The patients started the treatment with 80 mg valsartan daily, which could be up-titrated to 320 mg daily or combined with hydrochlorothiazide (HCTZ) in a fixed-dose combination to achieve target BP. The results of the VIC-TORY trial showed that valsartan and the FDC of valsartan and hydrochlorothiazide effectively reduce BP in patients with mild to moderate arterial hypertension, and have a very good tolerability profile.KLJUČNE RIJEČI: arterijska hipertenzija, arterijski tlak, djelotvornost, sigurnost, valsartan.
SAŽETAK: Među 67 analiziranih čimbenika visoki arterijski tlak (AT) identificiran je kao glavni čimbenik rizika za smrtni ishod i invalidnost. Kontrola vrijednosti AT-a još je uvijek daleko od razine koja bi bila nužna za smanjenje kardiovaskularnog rizika, a liječenje bolesnika s arterijskom hipertenzijom i dalje je izazov u svakodnevnoj kliničkoj praksi. Smanjenje učestalosti kardiovaskularnih događaja tijekom liječenja perindoprilom potkrepljuje koncept dodatnih zaštitnih kardiovaskularnih učinaka perindoprila i uz snizivanje vrijednosti AT-a. Učinkovita kontrola AT-a, kao što je to dokazano u kliničkim studijama s Krkinim perindoprilom i njegovim fiksnim kombinacijama doza s indapamidom I amlodipinom, zajedno s dobrom podnošljivošću i pogodnim jednodnevnim doziranjem, u pacijenata dovodi do pozitivnog učinka na ustrajnost liječenja, što je ključan korak prema postizanju ciljnih vrijednosti AT-a.SUMMARY: High blood pressure has been identified as the leading risk factor, among 67 studied, for death and disability. Blood pressure control is still far from what would be necessary to reduce the cardiovascular risk. The treatment of hypertensive patients remains a challenging issue in daily clinical practice. The reduction in cardiovascular events with perindopril supports the concept of cardiovascular protective effects of perindopril beyond blood pressure lowering. Effective blood pressure control, as demonstrated in clinical studies with Krka's perindopril and its fixed-dose combinations with indapamide and amlodipine, together with good tolerability and convenient once-daily dosing, have a positive impact on patients' adherence to the treatment -which is a crucial step towards reaching the blood pressure targets.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.